Sinogen Pharmaceutical Was Selected into the 2022 China Medical and Healthcare Industry Investment and Financing Honor List

On the evening of April 26, 2023, CHC Medical Consulting and CITIC Securities officially released the "2022 China Medical and Healthcare Industry Investment and Financing Honor List". As an authoritative ranking that leads the investment and financing trend of China's medical and healthcare industry, this Honor List has selected a total of 14 awards from four categories: investment institutions, enterprises, investors, and law firms. Sinogen Pharmaceutical has been honored on the list for its outstanding performance in 2022 and has been awarded the "Top 50 Medical and Healthcare Enterprises with the Most Investment Value in 2022" honor.

The "China Medical and Healthcare Industry Investment and Financing Honor List" was jointly launched by CHC Medical Consulting and CITIC Securities. Investment institutions, investors, innovative enterprises, and other industry participants who made outstanding contributions to the development and investment and financing of the medical and healthcare industry in the previous year were selected through data statistics, horizontal comparison, and comprehensive analysis. The list recognizes their valued contributions and sets industry benchmarks. Through five years of deep cultivation, the Honor List selection has become one of the important wind indicators for the development and investment and financing of China's medical and healthcare industry.